Pharmacokinetics of haloperidol: an update

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• Haloperidol is a crucial antipsychotic for schizophrenia treatment.
• Understanding haloperidol's biotransformation is vital for managing patient therapy and drug interactions.

Purpose of the Study:

• To elucidate the enzymatic pathways involved in haloperidol metabolism.
• To investigate the role of cytochrome P450 (CYP) enzymes, particularly CYP3A4, in haloperidol disposition.
• To identify potential pharmacokinetic drug interactions with haloperidol.

Main Methods:

• In vitro studies using human liver microsomes to assess enzyme kinetics.
• Analysis of haloperidol and its metabolites.
• Evaluation of drug interaction studies involving coadministration of haloperidol with other medications.

Main Results:

• Hepatic clearance of haloperidol is dominated by glucuronidation, followed by reduction and CYP-mediated oxidation.
• CYP3A4 is identified as the major enzyme responsible for haloperidol's oxidative metabolism in humans.
• Significant variations in CYP-mediated reaction rates were observed, contrasting with minor variations in glucuronidation and reduction pathways.
• Haloperidol and reduced haloperidol interact with CYP3A4 and CYP2D6, affecting their activity.
• Co-administration with certain drugs (e.g., carbamazepine, rifampicin) significantly alters haloperidol pharmacokinetics, potentially leading to clinical consequences.

Conclusions:

• Haloperidol's metabolism is complex, involving multiple enzymatic pathways with significant inter-individual variability, particularly in CYP-mediated reactions.
• CYP3A4 plays a central role in haloperidol biotransformation.
• Clinically significant drug interactions with haloperidol are possible, necessitating careful consideration of concomitant medications.
• Pharmacogenetic factors, especially related to CYP2D6, may influence haloperidol disposition, though in vitro and in vivo data present some discrepancies.